Related Experiment Video
Updated: Mar 21, 2026
Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
Published on: August 6, 2021
Investigational drugs for retinal vein occlusion
1a Ophthalmology Department , University Hospital Necker-Enfants Malades , Paris , France.
Introduction:
Retinal vein occlusion (RVO) is the second most common retinal vascular disorder. This multifactorial disease frequently leads to visual impairment. Some risk factors for RVO can be managed prophylactically. Given the complex physiopathology of RVO, most of the latest therapeutic strategies focus on secondary clinical features (such as macular oedema and neovascularization).
Areas Covered:
This author reviews ongoing, prospective, open-label Phase I and Phase II clinical trials of novels treatments for RVO (primarily intravitreal steroids and anti-VEGF agents). Specifically, they review the pharmacokinetics, safety profile, study design and adverse events associated with innovative drugs in clinical development.
Expert Opinion:
A number of innovative, early-phase clinical trials are based on combination therapy with an anti-VEGF agent and steroids. There is good evidence that early treatment of RVO has clinical benefits. Larger, randomized studies are now required for a better understanding of patient selection, treatment timing and dosing, and thus the optimized use of novel drugs and medical devices.
Insights
New treatments for retinal vein occlusion (RVO), including combination therapies, show promise. Early intervention is beneficial, but further research is needed to optimize patient selection and drug usage for this common vascular disorder.
Area of Science:
- Ophthalmology
- Vascular Medicine
- Pharmacology
Background:
- Retinal vein occlusion (RVO) is a prevalent retinal vascular disorder causing visual impairment.
- Its complex pathophysiology necessitates treatments targeting secondary complications like macular edema and neovascularization.
- Prophylactic management of certain risk factors is possible.
Purpose of the Study:
- To review ongoing Phase I and II clinical trials for novel RVO treatments.
- To analyze the pharmacokinetics, safety, and adverse events of investigational drugs.
- To assess innovative therapeutic strategies, including combination therapies.
Main Methods:
- Review of prospective, open-label clinical trials.
- Analysis of data on intravitreal steroids and anti-VEGF agents.
- Evaluation of study designs and drug development.
Main Results:
- Innovative trials are exploring combination therapy with anti-VEGF agents and steroids.
- Early treatment of RVO demonstrates clinical benefits.
- Pharmacokinetic and safety profiles of novel drugs are under investigation.
Conclusions:
- Combination therapy is a focus of current RVO research.
- Early RVO treatment is clinically advantageous.
- Further randomized studies are essential for optimizing treatment protocols, patient selection, and drug/device utilization.
